CLEC2D

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

Retrieved on: 
Lunedì, Aprile 8, 2024
Immunotherapy, Patient, Neoplasm, RNA, Novel, Cancer, AACR, CLEC2D, Therapy, NK, CD161

WALTHAM, Mass., April 8, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today presented preclinical data supporting the combination potential of IMT-009 with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting (AACR 2024) in San Diego, California.

Key Points: 
  • This need has fueled our work to develop IMT-009 as a differentiated cancer treatment option for patients," said Annalisa D'Andrea, Chief Scientific Officer at Immunitas.
  • "The preclinical data presented at AACR build upon this innovation, supporting potential for clinical benefit through combination approaches featuring IMT-009 and anti-PD-1 treatments."
  • The data presented at AACR 2024 build upon these preclinical data, reinforcing CD161 as a rational immunotherapy target with the potential to enhance T cell-mediated anti-tumor activity across a range of tumors.
  • Together these data support clinical assessment of IMT-009 treatment in combination with anti-PD-(L)1 approaches in patients refractory to anti-PD-(L)1 treatment alone.

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting

Retrieved on: 
Lunedì, Dicembre 4, 2023
Acquisition, Therapy, ASH, CLEC2D, Immunoglobulin G, Biotechnology, Patient, Neoplasm, Checkmate, Hematology, Regeneron Pharmaceuticals, TLR9, Cancer, SITC, CMO, Bone marrow, Society, CD161, DSM-IV codes, Biology, NK, Drug development, Pharmaceutical industry, Vaccine

WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO). The company also announced it will present new data supporting continued clinical development of its lead program IMT-009 for solid tumors and hematological malignancies at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023).

Key Points: 
  • Seasoned biotech executive James Wooldridge, M.D., named Chief Medical Officer to support advancement of immuno-oncology pipeline
    WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO).
  • Dr. Wooldridge has served as Acting CMO since June 2023 and has been an advisor to the Company since October 2022.
  • "We are pleased to announce Jim's appointment as our Chief Medical Officer as we continue progressing toward our goal of providing groundbreaking therapeutic solutions for patients with cancer," said Amanda Wagner, Chief Executive Officer of Immunitas.
  • He previously served as the Chief Medical Officer at Checkmate Pharmaceuticals leading up to the company's acquisition by Regeneron.

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

Retrieved on: 
Martedì, Ottobre 31, 2023
Society for Immunotherapy of Cancer, Neoplasm, Therapy, DC, TLR9, SITC, Immunotherapy, NK, CLEC2D, Society, Cancer, Patient, Myelocyte, TLR, Vaccine

WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), held November 1-5.

Key Points: 
  • In vitro proof-of-concept for novel myeloid and B cell modulating anti-CLEC2D-TLR9 agonist conjugate program, a compelling immunotherapeutic approach to induce T and NK cell recruitment in tumors with otherwise low immunological activity
    WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), held November 1-5.
  • Title: Anti CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid DCs and B cells leading to robust TLR pathway activation and inflammatory cytokine production

Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers

Retrieved on: 
Venerdì, Agosto 11, 2023
US Foods, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLT1, Pharmacokinetics, NK, Doctor of Philosophy, Trial of the century, CLEC2D, Investigational New Drug, Patient, Immunoglobulin G, TME, Holy Grail, Oncology, FDA, IND, Food, Safety, Vaccine, Pharmaceutical industry, Pembrolizumab

India, Aug. 11, 2023 /PRNewswire/ -- Zumutor Biologics Inc "Zumutor", a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers.

Key Points: 
  • India, Aug. 11, 2023 /PRNewswire/ -- Zumutor Biologics Inc "Zumutor", a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers.
  • ZM008 is a human IgG1 monoclonal antibody against LLT1 (CLEC2D), which disrupts the interaction of LLT1-CD161 between human immune cells and Tumor cells resulting in antitumor effects of ZM008 in monotherapy.
  • "The U.S. Food and Drug Administration's approval of ZM008 IND application is an important milestone for Zumutor and a clear recognition of the intriguing preclinical data supporting novel/non overlapping mode of actions, generated thus far.
  • "We believe that newer therapies like ZM008 will usher in options for patients and translate to better clinical outcomes.

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

Retrieved on: 
Mercoledì, Gennaio 4, 2023
Internal medicine, Bayer, Lymphatic system, Patient, University, CLEC2D, Biotechnology, Dana–Farber Cancer Institute, Investment, Drug development, Tulane University School of Medicine, MGH, NK, Safety, Lymphoma, FC, Regeneron Pharmaceuticals, Immunoglobulin G, Multimedia, Therapy, Sarah Cannon Research Institute, Principal, Lung cancer, Drug, Eli Lilly, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, Research, CD161, Cancer, Acquisition, Machine learning, Oncology, MIT, Pharmaceutical industry

WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the first patient has been dosed in a Phase 1/2a clinical trial evaluating use of novel cancer immunotherapeutic IMT-009 in solid tumors and hematologic malignancies. The company also announced the addition of James Wooldridge, M.D., to their Clinical Advisory Board.

Key Points: 
  • We look forward to further investigation of IMT-009 and its potential for patients awaiting improved treatment options."
  • The trial will subsequently transition into Phase 2 to assess the safety and efficacy of IMT-009 as a monotherapy and in combination with another anticancer agent.
  • The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D).
  • Immunitas is a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.

Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Mercoledì, Ottobre 5, 2022
Doctor of Philosophy, Therapy, National Autonomous University of Mexico, Bayer, MGH, IND, Recommended exposure limit, Machine learning, Investment, SITC, University of Buenos Aires, Diversity, Neoplasm, Patient, B cell, Committee, Research, NIH, NIH Director's New Innovator Award, Annual general meeting, Multimedia, Immunotherapy, Community, Stanford University School of Medicine, CD161, Coronavirus Scientific Advisory Board (Turkey), Cancer, New, Company, National Autonomous University, Department, Society, Biomedical sciences, Dana–Farber Cancer Institute, Rockefeller University, CLEC2D, MIT, Safety, Physiology, NK, Lymphatic system, Society for Immunotherapy of Cancer, View, Pharmaceutical industry, Vaccine, Online gambling, Immunology, Biology

WALTHAM, Mass., Oct. 5, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced they will present preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held both virtually and in Boston from November 8-12, 2022. The company also announced the addition of Juliana Idoyaga, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • The SITC presentation will demonstrate the potential of IMT-009 as a novel cancer immunotherapy to treat solid tumors and hematological malignancies.
  • Poster Presentation Details for IMT-009:
    Date/Time:All poster presentations are made available by the conference on November 10, 2022.
  • The SITC poster presentation will be available on the Immunitas Therapeutics website on November 10, 2022.
  • Immunitas is a precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

Retrieved on: 
Mercoledì, Settembre 21, 2022
Therapy, Safety, CD161, Machine learning, FDA, Food, MIT, IND, Recommender system, Bayer, Investment, Computational biology, NK, Patient, Dana–Farber Cancer Institute, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Clinical trial, CLEC2D, Lymphatic system, Investigational New Drug, MGH, Multimedia, View, Pharmaceutical industry

WALTHAM, Mass., Sept. 21, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D). The trial will then transition into Phase 2 with multiple expansion cohorts to assess the safety and efficacy of IMT-009 alone or in combination with another antineoplastic agent.

Key Points: 
  • "We are thrilled to advance IMT-009 to the clinic as we believe it represents a new wave of immuno-oncology agents with transformative potential in both hematological malignancies and solid tumors," said Seng-Lai "Thomas" Tan, Ph.D., Chief Scientific Officer of Immunitas Therapeutics.
  • "IMT-009 is a first-in-class therapeutic with exciting potential for efficacy in a broad range of tumor types.
  • I applaud the team at Immunitas that has driven it forward, and our academic founders who originally identified CD161 as an inhibitory T-cell target.
  • Immunitas is a precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.